|
THE AGE OF THE ANTIBODY HAS COMMENCED
Antibody-based
drugs, in particular monoclonal antibody-based products, are on the cusp
of significant commercial growth. New developments are spurred in
part by advances in technology that have now surmounted previous
technical barriers to commercialization.
According to a soon-to-be-released BUSINESS
COMMUNICATIONS CO., INC., study RC-088U Antibody for Therapeutic
and Diagnostic Imaging Applications, the total
worldwide market is estimated at nearly $2.8 billion in 1999, and is
forecast to grow to almost $9.8 billion in 2004. With the rollout of
dozens of new antibody products and expanded indications for existing
products expected during the forecast period, the AAGR
(average annual growth rate) for this sector as a whole is projected at
21.8%.
As of August 1999, there were 17 therapeutic and
diagnostic monoclonal antibody products on the U.S. market. Worldwide,
there were more than 700 monoclonal antibody products in
development by more than 260 companies for the treatment of virtually
every debilitating disease. Approximately 220 of these monoclonal antibody
products were in clinical trials.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA),
monoclonal antibody products represented approximately 37% of all
biotechnology products
in development by its members.
Therapeutic applications represent over 99% of
the market, and will grow at an average annual rate of 21.6% through the
period, thereby growing from $3.6 million in 1999 to $9.7 million in 2004.
Still in its inception stage in the late 90s,
diagnostic-imaging applications will grow at a fast AAGR of nearly 50% to
reach $196 million by 2004.
This report analyzes and assesses therapeutic and
in vivo diagnostic imaging applications of antibodies in human medicine.
The document is intended to be comprehensive with respect to products as
well as applications. The scope of the study is worldwide and provides a
comprehensive analysis of the current markets for antibody drugs and, in
particular, the market potential of promising drugs and technologies under
development. Included are both polyclonal and monoclonal antibodies.
Excluded are therapeutic and diagnostic imaging antibodies for veterinary
use. Also excluded are in vitro immunoassay applications of antibodies.
WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC
IMAGING ANTIBODIES, 1999-2004
($ Millions)
| |
1999 |
2004 |
AAGR %
1999-2004 |
| Therapeutic |
3,637 |
9,656 |
21.6 |
| Diagnostic Imaging |
26 |
196 |
49.8 |
| Total |
3,663 |
9,852 |
21.8 |
RC-088U Antibody for therapeutic and
Diagnostic Imaging Applications
Published: December 1999
Data and analysis provided courtesy of
BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT
06855, Telephone: (203) 853-4266; ext. 309, Email: publisher@bccresearch.com |
